We believe that earlier detection is the key to longevity. Lucence can provide you and your patients with insights before symptoms even appear. These insights help guide personalized health action plans so that
your patients can receive the most informed care possible.
Our solutions for screening and health risk assessment
LucenceINSIGHT is a multi-cancer early detection (MCED) next-generation sequencing (NGS) blood test that screens for up to 50 cancers with 99% specificity (low false-positives).
The test uses Lucence's mirror barcoding technology to detect ctDNA, ctRNA, and viral DNA. It can then predict tumor location with machine learning.
LucenceLONGEVITY is a combination of our LucenceINSIGHT 50 and CardioHemeRISK tests.
LucenceINSIGHT 50 is a multi-cancer early detection (MCED) next-generation sequencing (NGS) blood test that screens for 50 cancers with 99% specificity (low false-positives).
CardioHemeRISK is a next-generation sequencing (NGS) blood test. The test detects clonal hematopoiesis (CH) mutations to assess the risk of developing heart attack, stroke and leukemia.
Ordering Process
CardioHemeRISK™: Report ready in 12 working days
LucenceINSIGHT®: Report ready in 15-18 working days
LucenceLONGEVITY™: Report ready in 12 working days
Frequently Asked Questions
Clonal hematopoiesis (CH) is a common disorder acquired as an age- and lifestyle-related inflammatory process.
It starts typically above age 40 when one blood stem cell develops a mutation and begins making lots of blood cells (clonal expansion) with the same mutation. It is not cancer.
This increases the risk of developing cardiovascular and hematological conditions such as heart attack, stroke and leukemia.
Find our more about our CardioHemeRISK test that detects CH with a single blood draw.MCED testing complements other screening tests to improve the chances of early cancer detection. MCED testing is not meant to replace cancer screening tests but should be used in addition to routine screening tests.
LucenceINSIGHT is recommended for
-
those aged 40+
-
have elevated risk of cancer (due to family history, diet, and lifestyle)
LucenceINSIGHT is NOT recommended for individuals
-
who are pregnant
-
who have been in cancer remission for <3 years
Avoid heavy meals 4 hours before blood draw. Blood should be drawn before dialysis (if applicable).
CardioHemeRISK is recommended for-
healthy individuals aged above 40 and below 80
-
cancer survivors previously treated with chemotherapy or radiation
-
individuals with history of atherosclerotic disease such as coronary artery disease or ischemic stroke
-
healthy individuals aged above 40 with additional risk factors for atherosclerotic disease such as family history, hypertension, hyperlipidemia.
-
Contact us to request for a sample collection kit.
After ordering the test, patients will be required to draw 2-3 tubes of blood. The blood sample is then sent to Lucence laboratory for testing. The report is generated and sent over to your clinic.
CardioHemeRISK: Report ready in 12 working days
LucenceINSIGHT: Report ready in 10-18 working days
LucenceLONGEVITY: Report ready in 12 working daysLucenceINSIGHT
A negative LucenceINSIGHT test result indicates that the test did not find a cancer signal in the patient’s blood. However this does not mean the patient is cancer free as false negatives do occur. We recommend patients to continue with routine cancer screening and repeat LucenceINSIGHT testing annually to complement other cancer screening tests.
A positive LucenceINSIGHT test result indicates that the test detected a cancer signal in the patient’s blood, indicating a possible presence of cancer. A positive result is not enough to confirm a cancer diagnosis as false positives do occur. We recommend that the patient be sent to a specialist for further confirmatory testing such as imaging, laboratory testing, endoscopy and tissue diagnoses.CardioHemeRISK
CardioHemeRISK scores are categorised into-
average risk/mildly elevated risk
-
moderately elevated risk
-
high risk
Those with moderately elevated risk and high risk are recommended to repeat the test annually. Those with average risk/mildly elevated risk are recommended to repeat the test every 3 years.
Refer to the CardioHemeRISK brochure on how to interpret the CardioHemeRISK score according to risk categorisation.-
Our strategic collaborator
Our research collaborators
